SEARCH

SEARCH BY CITATION

References

  • 1
    Herbst RS,Giaccone G,Schiller JH,Natale RB,Miller V,Manegold C,Scagliotti G,Rosell R,Oliff I,Reeves JA,Wolf MK,Krebs AD, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 2004; 22: 78594.
  • 2
    Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 3
    Paez JG,Janne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 4
    Perou CM,Sorlie T,Eisen MB,van de Rijn M,Jeffrey SS,Rees CA,Pollack JR,Ross DT,Johnsen H,Akslen LA,Fluge O,Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 74752.
  • 5
    Sorlie T,Perou CM,Tibshirani R,Aas T,Geisler S,Johnsen H,Hastie T,Eisen MB,van de Rijn M,Jeffrey SS,Thorsen T,Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 1086974.
  • 6
    Sorlie T,Tibshirani R,Parker J,Hastie T,Marron JS,Nobel A,Deng S,Johnsen H,Pesich R,Geisler S,Demeter J,Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 841823.
  • 7
    Carey LA,Perou CM,Livasy CA,Dressler LG,Cowan D,Conway K,Karaca G,Troester MA,Tse CK,Edmiston S,Deming SL,Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006; 295: 2492502.
  • 8
    Hu Z,Fan C,Oh DS,Marron JS,He X,Qaqish BF,Livasy C,Carey LA,Reynolds E,Dressler L,Nobel A,Parker J, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
  • 9
    Sorlie T,Wang Y,Xiao C,Johnsen H,Naume B,Samaha RR,Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
  • 10
    Sotiriou C,Neo SY,McShane LM,Korn EL,Long PM,Jazaeri A,Martiat P,Fox SB,Harris AL,Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 103938.
  • 11
    Kapp AV,Jeffrey SS,Langerod A,Borresen-Dale AL,Han W,Noh DY,Bukholm IR,Nicolau M,Brown PO,Tibshirani R. Discovery and validation of breast cancer subtypes. BMC Genomics 2006; 7: 231.
  • 12
    Bertucci F,Finetti P,Rougemont J,Charafe-Jauffret E,Cervera N,Tarpin C,Nguyen C,Xerri L,Houlgatte R,Jacquemier J,Viens P,Birnbaum D. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65: 21708.
  • 13
    Van Laere SJ,Van den Eynden GG,Van der Auwera I,Vandenberghe M,van Dam P,Van Marck EA,van Golen KL,Vermeulen PB,Dirix LY. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95: 24355.
  • 14
    Yu K,Lee CH,Tan PH,Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004; 10: 550817.
  • 15
    Birnbaum D,Bertucci F,Ginestier C,Tagett R,Jacquemier J,Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminous ?. Int J Oncol 2004; 25: 24958.
  • 16
    Cleator S,Heller W,Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 23544.
  • 17
    Adelaide J,Finetti P,Bekhouche I,Repellini L,Geneix J,Sircoulomb F,Charafe-Jauffret E,Desplans J,Parzy D,Schoenmakers E,Viens P,Jacquemier J, et al. Integrated profiling of basal and luminal A breast cancers. Cancer Res, in press.
  • 18
    Hess KR,Anderson K,Symmans WF,Valero V,Ibrahim N,Mejia JA,Booser D,Theriault RL,Buzdar AU,Dempsey PJ,Rouzier R,Sneige N, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 423644.
  • 19
    Bertucci F,Finetti P,Cervera N,Charafe-Jauffret E,Mamessier E,Adelaide J,Debono S,Houvenaeghel G,Maraninchi D,Viens P,Charpin C,Jacquemier J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66: 463644.
  • 20
    Reyal F,Stransky N,Bernard-Pierrot I,Vincent-Salomon A,de Rycke Y,Elvin P,Cassidy A,Graham A,Spraggon C,Desille Y,Fourquet A,Nos C, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes–a study of 130 invasive ductal breast carcinomas. Cancer Res 2005; 65: 137683.
  • 21
    Moyano JV,Evans JR,Chen F,Lu M,Werner ME,Yehiely F,Diaz LK,Turbin D,Karaca G,Wiley E,Nielsen TO,Perou CM, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 26170.
  • 22
    Livasy CA,Karaca G,Nanda R,Tretiakova MS,Olopade OI,Moore DT,Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 26471.
  • 23
    Nielsen TO,Hsu FD,Jensen K,Cheang M,Karaca G,Hu Z,Hernandez-Boussard T,Livasy C,Cowan D,Dressler L,Akslen LA,Ragaz J, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 536774.
  • 24
    Yehiely F,Moyano JV,Evans JR,Nielsen TO,Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006; 12: 53744.
  • 25
    Rakha EA,El-Sayed ME,Green AR,Lee AH,Robertson JF,Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 2532.
  • 26
    Sasa M,Bando Y,Takahashi M,Hirose T,Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008; 97: 304.
  • 27
    Tan DS,Marchio C,Jones RL,Savage K,Smith IE,Dowsett M,Reis-Filho JS. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2007.
  • 28
    Tischkowitz M,Brunet JS,Begin LR,Huntsman DG,Cheang MC,Akslen LA,Nielsen TO,Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7: 134.
  • 29
    Bidard FC,Conforti R,Boulet T,Michiels S,Delaloge S,Andre F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol 2007; 18: 12856.
  • 30
    Kreike B,van Kouwenhove M,Horlings H,Weigelt B,Peterse H,Bartelink H,van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65
  • 31
    Rakha EA,Tan DS,Foulkes WD,Ellis IO,Tutt A,Nielsen TO,Reis-Filho JS Are triple negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007; 9: R80.